絞り込み

17054

広告

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab.

著者 Nowicki TS , Berent-Maoz B , Cheung-Lau GC , Huang RR , Wang X , Tsoi J , Kaplan-Lefko PJ , Cabrera P , Tran J , Pang J , Macabali MH , Perez Garcilazo I , Baselga Carretero I , Kalbasi A , Cochran AJ , Grasso CS , Hu-Lieskovan S , Chmielowski B , Comin-A
Clin Cancer Res.2018 Dec 20 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Medical

Transgenic adoptive cell therapy (ACT) targeting the tumor antigen NY-ESO-1 can be effective for the treatment of sarcoma and melanoma. Preclinical models have shown that this therapy can be improved with the addition of dendritic cell (DC) vaccination and immune checkpoint blockade. We studied the safety, feasibility, and antitumor efficacy of transgenic ACT with DC vaccination, with and without CTLA-4 blockade with ipilimumab.
PMID: 30573690 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード